Photo of Lorenzo Trippa,  PhD

Lorenzo Trippa, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 733-9115


ltrippa@jimmy.harvard.edu

Lorenzo Trippa, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Biostatistics, Harvard T.H. Chan School Of Public Health
  • Assistant Professor, biostat, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

Lorenzo Trippa is Assistant professor at the Dana Farber Cancer Institute, Biostatistics and Computational Biology Department, and at the Harvard School of Public Health, Biostatistics Department. He is trained in statistics and his research interests include the design of efficient clinical trials. He is especially interested in clinical trials for studying personalized medicine. His research interests include also the analysis of data generated for complex Bayesian adaptive clinical trials. He is currently collaborating with physicians at DFCI on applying Bayesian adaptation to trials of glioblastoma, a form of brain cancer, and incorporating genomic information in designing Bayesian clinical trials. He is also collaborating with physicians at Massachusetts General Hospital to design innovative trials for melanoma targeted therapies.

Publications

Powered by Harvard Catalyst
  • Madsen T, Braun D, Peng G, Parmigiani G, Trippa L. Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 2018. PubMed
  • O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. British Journal of Haematology 2018. PubMed
  • Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? 2018. PubMed
  • Alexander BM, Schoenfeld JD, Trippa L. Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy. N Engl J Med 2018; 378:1158-1159. PubMed
  • Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res 2017. PubMed
  • Ventz S, Cellamare M, Parmigiani G, Trippa L. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. Biostatistics 2017. PubMed
  • Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. 2017. PubMed
  • Ventz S, Alexander BM, Parmigiani G, Gelber RD, Trippa L. Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. J Clin Oncol 2017. PubMed
  • Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood 2017. PubMed
  • Ventz S, Barry WT, Parmigiani G, Trippa L. Bayesian response-adaptive designs for basket trials. Biometrics 2017. PubMed
  • Trippa L, Alexander BM. Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials. J Clin Oncol 2017. PubMed
  • Ren B, Bacallado S, Favaro S, Holmes S, Trippa L. Bayesian Nonparametric Ordination for the Analysis of Microbial Communities. Journal of the American Statistical Association 2018; 112:1430-1442. PubMed
  • Xu Y, Trippa L, Müller P, Ji Y. Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. 2016; 8:159-180. PubMed
  • Giecold G, Marco E, Garcia SP, Trippa L, Yuan GC. Robust lineage reconstruction from high-dimensional single-cell data. Nucleic Acids Res 2016. PubMed
  • Zhang Y, Trippa L, Parmigiani G. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers. Biometrics 2015. PubMed
  • Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. 2015. PubMed
  • Zhao L, Claggett B, Tian L, Uno H, Pfeffer MA, Solomon SD, Trippa L, Wei LJ. On the restricted mean survival time curve in survival analysis. Biometrics 2015. PubMed
  • Bowden J, Trippa L. Unbiased estimation for response adaptive clinical trials. 2015. PubMed
  • Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. 2015. PubMed
  • Alexander BM, Trippa L. Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. 2015; 17:765-6. PubMed
  • Ventz S, Trippa L. Bayesian designs and the control of frequentist characteristics: a practical solution. Biometrics 2015. PubMed
  • Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. 2015. PubMed
  • Marco E, Karp RL, Guo G, Robson P, Hart AH, Trippa L, Yuan GC. Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape. Proc Natl Acad Sci U S A 2014; 111:E5643-50. PubMed
  • Wason JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med 2014. PubMed
  • Bernau C, Riester M, Boulesteix AL, Parmigiani G, Huttenhower C, Waldron L, Trippa L. Cross-study validation for the assessment of prediction algorithms. Bioinformatics 2014; 30:i105-12. PubMed
  • Alexander BM, Trippa L. Progression-free survival: too much risk, not enough reward? 2014; 16:615-6. PubMed
  • Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute 2014. PubMed
  • Parmigiani G, Boca S, Ding J, Trippa L. Statistical tools and R software for cancer driver probabilities. Methods Mol Biol 2013; 1101:113-34. PubMed
  • Bourgeois EB, Johnson BN, McCoy AJ, Trippa L, Cohen AS, Marsh ED. A toolbox for spatiotemporal analysis of voltage-sensitive dye imaging data in brain slices. PLoS ONE 2014; 9:e108686. PubMed
  • Lorenzo Trippa, Eudocia Q. Lee, Patrick Y. Wen, Tracy T. Batchelor, Timothy Cloughesy, Giovanni Parmigiani and Brian M. Alexander. Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma J Clin Oncol 2012.
Hide